cutaneous leishmaniasis, infectious skin disease that is caused by any of multiple different trypanosome parasites in the genus Leishmania. The disease is the most commonly occurring form of leishmaniasis and is prevalent especially in the Americas, Asia, the Mediterranean, and the Middle East. Parasites that cause cutaneous leishmaniasis are transmitted to humans by the bite of female sand flies of the subfamily Phlebotominae.
Cutaneous leishmaniasis is characterized by the emergence of skin lesions, usually within several weeks or months of initial infection. Lesions frequently develop into ulcers and open sores with raised borders, which are susceptible to secondary infection with bacteria. Lesions may last for months or years, often resulting in lifelong scars and, in some cases, disability.
Treatment depends on various factors, including the causative Leishmania species and the geographic region where the infection was acquired. Examples of agents that may be used to treat cutaneous leishmaniasis include pentavalent antimony compounds, the antimicrobial agent miltefosine, and the antifungal drug amphotericin B.